DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality

Cytokine release syndrome (CRS) immune effector cell–associated neurotoxicity syndrome are the most notable toxicities of CD19 chimeric antigen receptor (CAR) T-cell therapy. In addition, CAR T-cell–mediated toxicities can involve any organ system, with varied impacts on outcomes, depending on patie...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Wudhikarn, Kitsada, Pennisi, Martina, Garcia-Recio, Marta, Flynn, Jessica R., Afuye, Aishat, Silverberg, Mari Lynne, Maloy, Molly A., Devlin, Sean M., Batlevi, Connie Lee, Shah, Gunjan L., Scordo, Michael, Palomba, Maria Lia, Dahi, Parastoo B., Sauter, Craig S., Santomasso, Bianca D., Mead, Elena, Perales, Miguel-Angel
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2020
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362382/
https://ncbi.nlm.nih.gov/pubmed/32614964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001972
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia